SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Dwight D. Eisenhower — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientDwight D. Eisenhower
Date of birth1890-10-14
IdentifiersMRN HR-ET015-SYN-TD; SSN (made up) 000-15-2673
Document date1956-03-16
AuthorRussell Okonkwo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Lipid review nine weeks after adding ezetimibe. [S]

History of Present Illness

Mr. Eisenhower returns for his lipid review. He has been back at full-time work for seven weeks, including two trips by air, without chest pain, breathlessness, or undue fatigue. He walks 40 minutes on most days and has started hitting golf balls at the practice range. He has had no muscle aches on atorvastatin and ezetimibe, and his home blood pressure averages 122/76. [S]

ElementDetail
Interval changeFull-time work for seven weeks; air travel tolerated
ExerciseWalking most days; golf practice resumed
Medication toleranceNo myalgia on atorvastatin and ezetimibe
Home blood pressureAverage 122/76
Nitroglycerin useNone

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fatigue or weight gain
CardiovascularNegativeNo chest pain, palpitations, or edema
RespiratoryNegativeNo breathlessness on stairs or walking
MusculoskeletalNegativeNo muscle aches or weakness
PsychiatricNegativeMood good; sleeping well; PHQ-2 score 0

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aspirin 81 mg delayed-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1955-09-24activeS
Ticagrelor 90 mg oral tablet, one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route1955-09-24 to 1956-09-28completedS
Atorvastatin 80 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1955-09-24activeS
Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1955-09-25activeS
Lisinopril 5 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1955-09-26 to 1956-01-12completedS
Lisinopril 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1956-01-12activeS
Ezetimibe 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1956-01-12activeS
Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tabletOne tablet under the tongue every 5 minutes as needed for chest pain, up to 3 dosesSublingual route1955-09-24activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1956-03-16Body height178cmS
1956-03-16Body weight78kgS
1956-03-16Body mass index (BMI) [Ratio]24.6kg/m2S
1956-03-16Systolic blood pressure124mm[Hg]S
1956-03-16Diastolic blood pressure76mm[Hg]S
1956-03-16Heart rate58/minS
1956-03-16Respiratory rate14/minS
1956-03-16Body temperature36.6CelS
1956-03-16Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1956-03-16Cholesterol [Mass/volume] in Serum or Plasma118mg/dL<=199 mg/dLNormalS
1956-03-16Cholesterol in HDL [Mass/volume] in Serum or Plasma44mg/dL>=40 mg/dLNormalS
1956-03-16Triglyceride [Mass/volume] in Serum or Plasma120mg/dL<=149 mg/dLNormalS
1956-03-16Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation50mg/dL<=99 mg/dLNormalS
1956-03-16Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-56 U/LNormalS
1956-03-16Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 1956-03-16; see the Vital Signs section. [S]

SystemFinding
GeneralWell and energetic
HeartRegular rhythm; no murmur or gallop
LungsClear
ExtremitiesNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Anterior ST-elevation myocardial infarction about four months before intake, treated with a drug-eluting stent to the left anterior descending artery; synthetic modern episode linked to the documented 1885 anterolateral infarctionactiveconfirmed I25.2S — Synthetic modern diagnosis; the 1955 infarction remains D in the history.
Coronary artery disease, single-vessel, after stenting; no anginaactiveconfirmed I25.10S — Synthetic diagnosis supporting secondary prevention.
Hyperlipidemia, on high-intensity statinactiveconfirmed E78.5S — Synthetic diagnosis; no cholesterol value from his lifetime is used.
Essential hypertensionactiveconfirmed I10S — Synthetic diagnosis; no blood pressure from his lifetime is used.
Former heavy cigarette smoker, quit about seven years before intakeactiveconfirmed Z87.891S — Synthetic coded history echoing the documented heavy smoking and quitting around 1949.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryLipid panel4 to 12 weeks after starting or changing therapy, then every 3 to 12 monthsCompleted todayNine weeks after adding ezetimibe, within the 4-to-12-week window of the ischemic heart disease and hyperlipidemia monographs and one week past the AMI monograph's 4-to-8-week window. LDL cholesterol 50 mg/dL, at goal
LaboratoryALTBaseline, then only with symptomsCompleted today26 U/L, normal; checked with the lipid panel because ezetimibe was added
LaboratoryBasic metabolic panel1 to 2 weeks after starting or changing an ACE inhibitor, then every 6 monthsUp to dateNormal two weeks after the lisinopril increase; next due in about four months
ExaminationBlood pressure, heart rate, weight and BMI, heart and lungs, edemaEvery visitCompleted todayBlood pressure 124/76 mmHg, weight 78.0 kg
Medication safetyAntiplatelet, statin, beta-blocker, and ACE inhibitor adherence and toleranceEvery visitCompleted todayTaking all doses; no bleeding beyond bruising; no myalgia
SurveyDepression screen (PHQ-2)Every visitCompleted todayScore 0
Self-managementTobacco useEvery visitCompleted todayAbstinent
Self-managementPhysical activity and dietEvery visitCompleted todayAt least 150 minutes a week of moderate activity
ImagingStress testing or repeat echocardiographyOnly with new or changing symptomsNot indicatedNo symptoms; routine surveillance testing is not recommended

Goal progress:

Guideline basis: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026)

Follow-up: Coronary disease review in about two months. Next scheduled visit 1956-05-11: seven-month coronary disease review after return to full-time work. [S]